Evidence map›Paper›PMID 34501249›Full record

ReviewJournal of clinical medicine2021

Hyperthermic Intrathoracic Chemotherapy for Malignant Pleural Mesothelioma: The Forefront of Surgery-Based Multimodality Treatment.

Vittorio Aprile, Alessandra Lenzini, Filippo Lococo, Diana Bacchin, Stylianos Korasidis, Maria Giovanna Mastromarino, Giovanni Guglielmi, Gerardo Palmiero, Marcello Carlo Ambrogi, Marco Lucchi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. TNM Staging System in Thymoma: A Critical Appraisal?Journal of clinical medicine · 2024
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Vittorio AprileUnit of Thoracic Surgery, Department of Critical Area and Surgical, Medical and Molecular Pathology, University of Pisa, 56122 Pisa, Italy.
Alessandra LenziniUnit of Thoracic Surgery, Department of Critical Area and Surgical, Medical and Molecular Pathology, University of Pisa, 56122 Pisa, Italy.
Filippo LococoThoracic Surgery Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Diana BacchinUnit of Thoracic Surgery, Department of Critical Area and Surgical, Medical and Molecular Pathology, University of Pisa, 56122 Pisa, Italy.ORCID 0000-0002-5706-0974
Stylianos KorasidisUnit of Thoracic Surgery, Department of Critical Area and Surgical, Medical and Molecular Pathology, University of Pisa, 56122 Pisa, Italy.
Maria Giovanna MastromarinoUnit of Thoracic Surgery, Department of Critical Area and Surgical, Medical and Molecular Pathology, University of Pisa, 56122 Pisa, Italy.
Giovanni GuglielmiOccupational Health Department, U.O. Medicina Preventiva del Lavoro, Azienda Ospedaliero-Universitaria Pisana, 56122 Pisa, Italy.
Gerardo PalmieroPneumology Unit, Versilia Hospital, 55049 Camaiore, Italy.
Marcello Carlo AmbrogiUnit of Thoracic Surgery, Department of Critical Area and Surgical, Medical and Molecular Pathology, University of Pisa, 56122 Pisa, Italy.
Marco LucchiUnit of Thoracic Surgery, Department of Critical Area and Surgical, Medical and Molecular Pathology, University of Pisa, 56122 Pisa, Italy.
University of Pisa · ITAgostino Gemelli University Polyclinic · ITAzienda Ospedaliera Universitaria Pisana · ITOspedale Versilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMalignant Pleural Mesothelioma (MPM) is characterized by an aggressive behavior and an inevitably fatal prognosis, whose treatment is still far from being standardized. The role of surgery is questionable since a radical resection is unattainable in most cases. Hyperthermic IntraTHOracic Chemotherapy (HITHOC) combines the advantages of antitumoral effects together with those of high temperature on the exposed tissues with the aim to improve surgical radicality. MATERIAL AND

methodsthis is a narrative review on the role of HITHOC in the management of MPM patients. To provide data on the beginnings and the historical evolution of this technique, we searched the available literature by selecting the more exhaustive papers on this topic.

resultsfrom 1994 to date different authors experimented HITHOC following a cytoreductive surgery in MPM, obtaining in most cases a good local control and a better overall survival associated to very low complication rate.

conclusionsHITHOC may be considered as a safe, feasible and effective procedure although there is a high heterogeneity between different protocols adopted worldwide. More structured studies are needed to reach a unanimous consensus on this technique.

Indexed as

chemotherapyHITHOChypertermialocal treatmentmesothelioma

Identifiers

PMID34501249
PMCPMC8432004
OpenAlexW3194646126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.